Cancer Therapy & Research Center
7979 Wurzbach Rd., San Antonio, TX 78229 (210) 450-1000
Toll free: 1-800-340-CTRC (2872)
Toll free: 1-800-340-CTRC (2872)
| Surveillance for low-risk non-muscle invasive bladder cancer: A Pilot Study | |||
|---|---|---|---|
| Principal Investigator: Robert Svatek, MD | IRB #: | ||
| Department Address: Department of Urology, 7703 Floyd Curl Drive, San Antonio, TX 78229 |
|
||
| Contact Person:
Izelda Zarate |
|||
Enrollment Notes: patients with bladder cancer |
|||
| The target age is: 18years of age | |||
Study Begin and End Date: January 2013- January 2015 |
|||
Eligibility Criteria: Men or women with a diagnosis of "superficial" (non-muscle invasive bladder cancer) |
|||
Type of Study: Intervention |
|||
| Funding Source: Cancer Therapy and Research Center | |||
| Detailed description of this study | |||
| In the U.S., guidelines for following patients with non-muscle invasive bladder cancer indicate that patients should undergo cystoscopy every 3 months for the first 2 years after diagnosis, then every 6 months for the next 2 years, and then yearly. This recommendation is based on expert opinion (Level 4 evidence). The European Association Urology (EAU) recommends a less frequent followup scheme (see Treatment plan below). Although such an approach could considerably decrease costs and burden during the follow-up period by examining patients less frequently, to date these surveillance approaches have never been assessed in a prospective manner. The goal of the study is to compare these 2 different approaches to surveillance for bladder cancer in terms of progression rates, direct and indirect costs, and patient satisfaction.
|
|||
Title: Phase III blinded study of immediate post-TURBT instillation of Gemcitabine versus Saline in patients with newly diagnosed or occasionally recurring grade I/II superficial bladder cancer.
